Cholesterol lipids of Borrelia burgdorferi form lipid rafts and are required for the bactericidal activity of a complement-independent antibody
- PMID: 20951967
- PMCID: PMC3010898
- DOI: 10.1016/j.chom.2010.09.001
Cholesterol lipids of Borrelia burgdorferi form lipid rafts and are required for the bactericidal activity of a complement-independent antibody
Abstract
Borrelia burgdorferi, the agent of Lyme disease, is unusual as it contains free cholesterol and cholesterol glycolipids. It is also susceptible to complement-independent bactericidal antibodies, such as CB2, a monoclonal IgG1 against outer surface protein B (OspB). We find that the bactericidal action of CB2 requires the presence of cholesterol glycolipids and cholesterol. Ultrastructural, biochemical, and biophysical analysis revealed that the bacterial cholesterol glycolipids exist as lipid raft-like microdomains in the outer membrane of cultured and mouse-derived B. burgdorferi and in model membranes from B. burgdorferi lipids. The order and size of the microdomains are temperature sensitive and correlate with the bactericidal activity of CB2. This study demonstrates the existence of cholesterol-containing lipid raft-like microdomains in a prokaryote, and we suggest that the temperature dependence of B. burgdorferi lipid raft organization may have significant implications in the transmission cycle of the spirochetes which are exposed to a range of temperatures.
Copyright © 2010 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Whole-genome DNA array analysis of the response of Borrelia burgdorferi to a bactericidal monoclonal antibody.Infect Immun. 2004 Apr;72(4):2035-44. doi: 10.1128/IAI.72.4.2035-2044.2004. Infect Immun. 2004. PMID: 15039324 Free PMC article.
-
Selective association of outer surface lipoproteins with the lipid rafts of Borrelia burgdorferi.mBio. 2014 Mar 11;5(2):e00899-14. doi: 10.1128/mBio.00899-14. mBio. 2014. PMID: 24618252 Free PMC article.
-
Proving lipid rafts exist: membrane domains in the prokaryote Borrelia burgdorferi have the same properties as eukaryotic lipid rafts.PLoS Pathog. 2013;9(5):e1003353. doi: 10.1371/journal.ppat.1003353. Epub 2013 May 16. PLoS Pathog. 2013. PMID: 23696733 Free PMC article.
-
Functional heterogeneity in the antibodies produced to Borrelia burgdorferi.Wien Klin Wochenschr. 1999 Dec 10;111(22-23):985-9. Wien Klin Wochenschr. 1999. PMID: 10666815 Review.
-
Immune evasion of Borrelia burgdorferi: insufficient killing of the pathogens by complement and antibody.Int J Med Microbiol. 2002 Jun;291 Suppl 33:141-6. doi: 10.1016/s1438-4221(02)80027-3. Int J Med Microbiol. 2002. PMID: 12141738 Review.
Cited by
-
Pathogenicity and virulence of Borrelia burgdorferi.Virulence. 2023 Dec;14(1):2265015. doi: 10.1080/21505594.2023.2265015. Epub 2023 Oct 9. Virulence. 2023. PMID: 37814488 Free PMC article. Review.
-
Cholesterol Contributes to Risk, Severity, and Machine Learning-Driven Diagnosis of Lyme Disease.Clin Infect Dis. 2023 Sep 18;77(6):839-847. doi: 10.1093/cid/ciad307. Clin Infect Dis. 2023. PMID: 37227948 Free PMC article.
-
A Borrelia burgdorferi LptD homolog is required for flipping of surface lipoproteins through the spirochetal outer membrane.Mol Microbiol. 2023 Jun;119(6):752-767. doi: 10.1111/mmi.15072. Epub 2023 May 12. Mol Microbiol. 2023. PMID: 37170643 Free PMC article.
-
Bacterial lipid biophysics and membrane organization.Curr Opin Microbiol. 2023 Aug;74:102315. doi: 10.1016/j.mib.2023.102315. Epub 2023 Apr 13. Curr Opin Microbiol. 2023. PMID: 37058914 Free PMC article. Review.
-
Agglutination of Borreliella burgdorferi by Transmission-Blocking OspA Monoclonal Antibodies and Monovalent Fab Fragments.Infect Immun. 2022 Sep 15;90(9):e0030622. doi: 10.1128/iai.00306-22. Epub 2022 Aug 24. Infect Immun. 2022. PMID: 36000876 Free PMC article.
References
-
- Becker M, Bunikis J, Lade BD, Dunn JJ, Barbour AG, Lawson CL. Structural investigation of Borrelia burgdorferi OspB, a bactericidal Fab target. J Biol Chem. 2005;280:17363–17370. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-GM-048596/GM/NIGMS NIH HHS/United States
- R37 AI027044/AI/NIAID NIH HHS/United States
- T32-AI-007539/AI/NIAID NIH HHS/United States
- P01 AI055621/AI/NIAID NIH HHS/United States
- R37-AI-027044/AI/NIAID NIH HHS/United States
- R01 AR040445/AR/NIAMS NIH HHS/United States
- R0I-AR-040445/AR/NIAMS NIH HHS/United States
- U54-AI-057158/AI/NIAID NIH HHS/United States
- R01 AI027044/AI/NIAID NIH HHS/United States
- T32 AI007539/AI/NIAID NIH HHS/United States
- R01 GM048596/GM/NIGMS NIH HHS/United States
- U54 AI057158/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical